Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) Shares Outstanding (Diluted Average) (2018 - 2020)

Historic Shares Outstanding (Diluted Average) for Cryo Cell International (CCEL) over the last 7 years, with Q2 2020 value amounting to $8.1 million.

  • Cryo Cell International's Shares Outstanding (Diluted Average) fell 358.21% to $8.1 million in Q2 2020 from the same period last year, while for May 2020 it was $8.1 million, marking a year-over-year decrease of 358.21%. This contributed to the annual value of $8.4 million for FY2019, which is 1272.08% up from last year.
  • Per Cryo Cell International's latest filing, its Shares Outstanding (Diluted Average) stood at $8.1 million for Q2 2020, which was down 358.21% from $8.1 million recorded in Q1 2020.
  • In the past 5 years, Cryo Cell International's Shares Outstanding (Diluted Average) ranged from a high of $8.4 million in Q3 2019 and a low of $7.5 million during Q4 2018
  • Its 3-year average for Shares Outstanding (Diluted Average) is $8.2 million, with a median of $8.4 million in 2018.
  • As far as peak fluctuations go, Cryo Cell International's Shares Outstanding (Diluted Average) surged by 1272.08% in 2019, and later tumbled by 358.21% in 2020.
  • Over the past 3 years, Cryo Cell International's Shares Outstanding (Diluted Average) (Quarter) stood at $7.5 million in 2018, then grew by 12.72% to $8.4 million in 2019, then dropped by 3.47% to $8.1 million in 2020.
  • Its Shares Outstanding (Diluted Average) was $8.1 million in Q2 2020, compared to $8.1 million in Q1 2020 and $8.4 million in Q4 2019.